Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4985MR)

This product GTTS-WQ4985MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4985MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5984MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ12748MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ520MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ9598MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ15441MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ14039MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ11855MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ13054MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW